Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 24 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Jagsonpal Pharmaceuticals Ltd

About the Company - Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1978PLC009181 and registration number is 009181. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 226.10 Cr. and Equity Capital is Rs. 13.10 Cr. for the Year ended 31/03/2022.
PharmaceuticalsT-210 J, Shahpur Jat, New Delhi Delhi
NamePosition Held
Mr. Rajpal Singh KochharChairman Emeritus
Mr. Manish GuptaManaging Director
Mr. Harsha RaghavanChairman & Non-Exe.Director
Mr. Prithipal Singh KochharNon Executive Director
Mr. Debasis Bikash NandyIndependent Director
Ms. Radhika Madhukar DudhatIndependent Director
Ms. Pallavi Dinodia GuptaIndependent Director

Jagsonpal Pharmaceuticals Ltd. Share Price Update

Share PriceValue
Previous Day₹293.90

Basic Stock Data of Jagsonpal Pharmaceuticals Ltd

Market Cap 814 Cr.
Current Price 309
High / Low515/280
Stock P/E33.2
Book Value 64.4
Dividend Yield1.61 %
ROCE25.6 %
ROE19.9 %
Face Value 5.00

Data Source:

Competitors of Jagsonpal Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Venus Remedies Ltd 488 Cr. 365430/14716.8 3520.00 %7.75 %5.90 % 10.0
Beta Drugs Ltd 1,259 Cr. 1,3101,595/60036.2 1480.00 %33.9 %28.6 % 10.0
Unichem Laboratories Ltd 3,835 Cr. 545580/272 3420.00 %4.58 %7.05 % 2.00
Par Drugs & Chemicals Ltd 262 Cr. 212248/12818.4 63.90.00 %23.0 %17.1 % 10.0
Bafna Pharmaceuticals Ltd 220 Cr. 92.9126/77.019.5 34.80.00 %15.9 %16.4 % 10.0
Industry Average194.8 Cr243.1818.18188.140%17.03%15.01%8.4

Jagsonpal Pharmaceuticals Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Operating Profit6.495.129.289.405.620.787.1812.918.645.448.638.373.40
OPM %11.37%11.95%17.17%15.80%10.32%1.52%11.85%21.33%14.37%9.81%14.35%14.47%7.20%
Other Income0.532.660.820.281.950.37-
Profit before tax6.617.399.719.397.140.443.8313.809.877.3210.099.965.28
Tax %17.85%30.85%29.45%30.24%24.23%31.82%23.50%24.49%21.07%23.50%25.87%25.00%24.81%
Net Profit5.435.106.856.565.410.312.9210.417.795.607.487.473.96
EPS in Rs2.071.952.612.502.

Jagsonpal Pharmaceuticals Ltd Quarterly Chart

Jagsonpal Pharmaceuticals Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit1710119126-119919263531
OPM %9%6%7%6%8%4%-9%6%5%10%12%15%13%
Other Income00001130134329
Profit before tax10332414-129922273537
Tax %26%28%16%30%20%18%1%20%16%22%29%23%
Net Profit7221312-127817192728
EPS in Rs2.850.700.810.451.244.53-4.412.763.006.517.2010.2010.82
Dividend Payout %18%72%62%22%8%2%-2%9%17%15%56%49%

Jagsonpal Pharmaceuticals Ltd Profit & Loss Yearly Chart

Jagsonpal Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:4%
5 Years:13%
3 Years:14%
Compounded Profit Growth
10 Years:32%
5 Years:35%
3 Years:54%
Stock Price CAGR
10 Years:40%
5 Years:60%
3 Years:57%
1 Year:-9%
Return on Equity
10 Years:7%
5 Years:13%
3 Years:17%
Last Year:20%

Jagsonpal Pharmaceuticals Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital13131313131313131313131313
Other Liabilities23212219222523283135313031
Total Liabilities156153156154159143130136147164164195209
Fixed Assets59585652522221222226232410
Other Assets96929810210812110511010912391170198
Total Assets156153156154159143130136147164164195209

Jagsonpal Pharmaceuticals Ltd Reserves and Borrowings Chart

Jagsonpal Pharmaceuticals Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 712849-3-2311128747
Cash from Investing Activity -5-3-1-0-241-3-1-11-2-26-58
Cash from Financing Activity 0-8-4-1-6-34-1-6-1-7-18-0
Net Cash Flow302215-624-019-36-11

Jagsonpal Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days8793115119106100734549252632
Inventory Days15212717317624629530716419113412281
Days Payable352829426056545976827664
Cash Conversion Cycle204192259252292339325150164777249
Working Capital Days1291301551711691741737666455936
ROCE %11%6%6%5%7%3%-10%9%9%18%20%26%

Jagsonpal Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Jagsonpal Pharmaceuticals Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
No. of Shareholders12,13112,54614,65514,35320,03117,10016,19414,95214,53514,08413,78216,041

Jagsonpal Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Jagsonpal Pharmaceuticals Ltd Shareholders

Jagsonpal Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Motilal Oswal S&P BSE Healthcare ETF830.040

Jagsonpal Pharmaceuticals Ltd ROCE Trend

Jagsonpal Pharmaceuticals Ltd EPS Trend

Jagsonpal Pharmaceuticals Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)10.207.486.513.002.75
Diluted EPS (Rs.)10.207.486.513.002.75
Cash EPS (Rs.)10.668.066.713.443.14
Book Value[Excl.RevalReserv]/Share (Rs.)60.6546.9643.5539.3936.89
Book Value[Incl.RevalReserv]/Share (Rs.)60.6549.9546.5442.3839.88
Dividend / Share (Rs.)
Revenue From Operations / Share (Rs.)90.3686.3071.7460.5364.22
PBDIT / Share (Rs.)15.2211.128.964.224.11
PBIT / Share (Rs.)14.7610.548.763.793.72
PBT / Share (Rs.)13.2910.438.353.593.44
Net Profit / Share (Rs.)10.207.486.513.002.75
PBDIT Margin (%)16.8412.8812.486.976.39
PBIT Margin (%)16.3412.2012.216.265.79
PBT Margin (%)14.7012.0811.635.935.35
Net Profit Margin (%)11.288.669.074.964.28
Return on Networth / Equity (%)16.8115.9214.957.627.46
Return on Capital Employeed (%)23.1020.5518.548.699.06
Return On Assets (%)13.7011.6210.385.355.31
Total Debt / Equity (X)
Asset Turnover Ratio (%)1.301.361.211.121.27
Current Ratio (X)5.973.242.982.893.46
Quick Ratio (X)5.222.372.252.002.30
Inventory Turnover Ratio (X)1.241.361.311.190.92
Dividend Payout Ratio (NP) (%)0.0053.5015.3516.6410.94
Dividend Payout Ratio (CP) (%)0.0049.6314.9114.559.59
Earning Retention Ratio (%)0.0046.5084.6583.3689.06
Cash Earning Retention Ratio (%)0.0050.3785.0985.4590.41
Interest Coverage Ratio (X)96.57102.1821.6121.5114.44
Interest Coverage Ratio (Post Tax) (X)74.0869.7016.7116.3110.68
Enterprise Value (Cr.)644.85795.42154.9612.3134.15
EV / Net Operating Revenue (X)2.723.520.820.070.20
EV / EBITDA (X)16.1727.316.601.113.17
MarketCap / Net Operating Revenue (X)3.213.631.110.280.40
Retention Ratios (%)0.0046.4984.6483.3589.05
Price / BV (X)4.786.681.830.440.71
Price / Net Operating Revenue (X)3.213.631.110.280.40

Jagsonpal Pharmaceuticals Ltd Profitability Ratios (%)

Jagsonpal Pharmaceuticals Ltd Liquidity Ratios

Jagsonpal Pharmaceuticals Ltd Liquidity Ratios (%)

Jagsonpal Pharmaceuticals Ltd Interest Coverage Ratios (%)

Jagsonpal Pharmaceuticals Ltd Valuation Ratios

Fair Value of Jagsonpal Pharmaceuticals Ltd Stock

Fair Value: ₹432.33

The stock is undervalued by 39.91% compared to the current price ₹309

*Investments are subject to market risks

Strength and Weakness of Jagsonpal Pharmaceuticals Ltd Stock

  1. The company has higher reserves (101.85 cr) compared to borrowings (17.54 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (172.46 cr) and profit (12.54 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 8.73 and average Dividend Yield of 10.56%.
  2. The stock has a low average ROCE of 9.17%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 115.25, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 197.92, which may not be favorable.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Jagsonpal Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE